ArticleBMC cancer2002
Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis.
Article in BMC cancer, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- p53 suppresses MHC class II presentation by intestinal epithelium to protect against radiation-induced gastrointestinal syndrome.Nature communications · 2024Article
- Microbial sophorolipids inhibit colorectal tumour cell growth in vitro and restore haematocrit in ApcApplied microbiology and biotechnology · 2022Article
- Effects of dietary aspirin on high-LET radiation-induced prostaglandin E2 levels and gastrointestinal tumorigenesis in ApcLife sciences in space research · 2021Article
- Article
- Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development.BMC cancer · 2020Article
- Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis.Cancer medicine · 2020Article
- Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives.International journal of molecular sciences · 2018Review
- Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression.Cell death & disease · 2015Article
- Chemopreventive effects of berberine on intestinal tumor development in Apcmin/+ mice.BMC gastroenterology · 2013Article
- Pro-neoplastic effects of amphiregulin in colorectal carcinogenesis.Journal of gastrointestinal cancer · 2013Article
- Cancer in inflammatory bowel disease: lessons from animal models.Current opinion in gastroenterology · 2012Review
- Supplementation by vitamin D compounds does not affect colonic tumor development in vitamin D sufficient murine models.Archives of biochemistry and biophysics · 2011Article
- A unique therapeutic approach to emesis and itch with a proanthocyanidin-rich genonutrient.Journal of translational medicine · 2008Article
- Age-related difference in susceptibility of Apc(Min/+) mice towards the chemopreventive efficacy of dietary aspirin and curcumin.British journal of cancer · 2003Article
- Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models.Mutation researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years it has become evident that nonsteroidal anti-inflammatory drugs, in particular aspirin represent a potential class of cancer chemotherapeutic agents. Despite the wealth of knowledge gained from epidemiological, clinical and animal studies, the effectiveness of aspirin to treat established gastrointestinal cancer has not been determined. The present study examines the ability of aspirin to treat established polyposis in Min/+ mice.
methodsMin/+ mice with established polyposis were treated orally once daily from 12-16 weeks of age with either drug vehicle or aspirin (25 mg/kg). Upon completion of treatment, the number, location and size of intestinal tumours was determined. Additional variables examined were the number of apoptotic cells within tumours and COX activity.
resultsAdministration of aspirin for 4 weeks to Min/+ mice produce no effect on tumour number compared to vehicle-treated Min/+ mice (65 +/- 8 vs. 63 +/- 9, respectively). In addition, aspirin had no effect on tumour size or location. However, aspirin treatment produced a greater than 2-fold (p<0.05) increase in the number of apoptotic positive cells within tumours and significantly decreased hepatic PGE2 content.
conclusionsAspirin was found to have no effect on tumour number and size when administered to Min/+ mice with established polyposis. The findings in the present study call in to question the utility of aspirin as a stand-alone treatment for established GI cancer. However, aspirin's ability to significantly promote apoptosis may render it suitable for use in combinatorial chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.